Loading...
Some studies of bisphosphonates have suggested that these drugs are associated with lower overall mortality. In this meta-analysis, researchers explored that benefit in 38 randomized, controlled trials of osteoporosis drugs (21 studies of bisphosphonates, 7 studies of selective estrogen-receptor modulators, and 10 studies of parathyroid hormone analogues and other drugs) that involved 102,000 patients. Minimum duration of evaluated studies was 1 year.
No evidence of an overall mortality benefit was observed in the pooled results. No mortality benefit was noted in subanalyses limited to the 21 bisphosphonate trials (≈45,000 participants) or limited to the 6 trials of zoledronate specifically (≈7000 participants).